-
Je něco špatně v tomto záznamu ?
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy
EJ. van Gennep, F. Claps, PJ. Bostrom, SF. Shariat, Y. Neuzillet, AR. Zlotta, C. Trombetta, M. Eckstein, LS. Mertens, R. Bussani, M. Burger, JL. Boormans, B. Wullich, A. Hartmann, R. Mayr, N. Pavan, R. Bartoletti, MC. Mir, D. Pouessel, J. van der...
Status neindexováno Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2023
PubMed Central
od 2021
ROAD: Directory of Open Access Scholarly Resources
od 2015
PubMed
39131875
DOI
10.3233/blc-230086
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed. OBJECTIVES: To evaluate the prognostic impact of lymph node (LN)-density on disease-specific survival (DSS) in patients with bladder cancer (BC) undergoing RC with pelvic lymph node dissection. METHODS: We analyzed a multi-institutional cohort of 1169 patients treated with upfront RC for cT1-4aN0M0 urothelial BCat nine centers. LN-densitywas calculated as the ratio of the number of positive LNs×100% to the number of LNs removed. The optimal LN-density cut-off value was defined by creating a time-dependent receiver operating characteristic (ROC) curve in pN patients. Univariable and multivariable Cox' regression analyses were used to assess the effect of conventional Tumor Nodes Metastasis (TNM) nodal staging system, LN-density and other LN-related variables on DSS in the pN-positive cohort. RESULTS: Of the 1169 patients, 463 (39.6%) patients had LN-involvement. The area under the ROC curve was 0.60 and the cut-off for LN-density was set at 20%, 223 of the pN-positive patients (48.2%) had a LN-density ≥ 20%. In multivariable models, the number of LN-metastases (HR 1.03, p = 0.005) and LN-density, either as continuous (HR 1.01, p = 0.013) or as categorical variable (HR 1.37, p = 0.014), were independently associated with worse DSS, whereas pN-stage was not. CONCLUSIONS: LN-density ≥ 20% was an independent predictor of worse DSS in BC patients with LN-involvement at RC. The integration of LN-density and other LN-parameters rather than only conventional pN-stage may contribute to a more refined risk-stratification in BC patients with nodal involvement.
Department of Pathology Institut Curie Paris France
Department of Pathology University of Trieste Trieste Italy
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Caritas St Josef Medical Center University of Regensburg Regensburg Germany
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Hôpital Foch UVSQ Paris Saclay University Suresnes France
Department of Urology Hospital Universitario La Ribera Valencia Spain
Department of Urology Leiden University Medical Center Leiden The Netherlands
Department of Urology Reinier de Graaf Hospital Delft The Netherlands
Department of Urology Turku University Hospital and University of Turku Turku Finland
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Molecular Oncology Team Institut Curie CNRS UMR144 PSL Research University Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018348
- 003
- CZ-PrNML
- 005
- 20241016081840.0
- 007
- ta
- 008
- 241008s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3233/BLC-230086 $2 doi
- 035 __
- $a (PubMed)39131875
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a van Gennep, Erik J $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands $u Department of Urology, Leiden University Medical Center, Leiden, The Netherlands
- 245 10
- $a Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy / $c EJ. van Gennep, F. Claps, PJ. Bostrom, SF. Shariat, Y. Neuzillet, AR. Zlotta, C. Trombetta, M. Eckstein, LS. Mertens, R. Bussani, M. Burger, JL. Boormans, B. Wullich, A. Hartmann, R. Mayr, N. Pavan, R. Bartoletti, MC. Mir, D. Pouessel, J. van der Hoeven, TH. van der Kwast, Y. Allory, TCM. Zuiverloon, Y. Lotan, BWG. van Rhijn
- 520 9_
- $a BACKGROUND: Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed. OBJECTIVES: To evaluate the prognostic impact of lymph node (LN)-density on disease-specific survival (DSS) in patients with bladder cancer (BC) undergoing RC with pelvic lymph node dissection. METHODS: We analyzed a multi-institutional cohort of 1169 patients treated with upfront RC for cT1-4aN0M0 urothelial BCat nine centers. LN-densitywas calculated as the ratio of the number of positive LNs×100% to the number of LNs removed. The optimal LN-density cut-off value was defined by creating a time-dependent receiver operating characteristic (ROC) curve in pN patients. Univariable and multivariable Cox' regression analyses were used to assess the effect of conventional Tumor Nodes Metastasis (TNM) nodal staging system, LN-density and other LN-related variables on DSS in the pN-positive cohort. RESULTS: Of the 1169 patients, 463 (39.6%) patients had LN-involvement. The area under the ROC curve was 0.60 and the cut-off for LN-density was set at 20%, 223 of the pN-positive patients (48.2%) had a LN-density ≥ 20%. In multivariable models, the number of LN-metastases (HR 1.03, p = 0.005) and LN-density, either as continuous (HR 1.01, p = 0.013) or as categorical variable (HR 1.37, p = 0.014), were independently associated with worse DSS, whereas pN-stage was not. CONCLUSIONS: LN-density ≥ 20% was an independent predictor of worse DSS in BC patients with LN-involvement at RC. The integration of LN-density and other LN-parameters rather than only conventional pN-stage may contribute to a more refined risk-stratification in BC patients with nodal involvement.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Claps, Francesco $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands $u Department of Urology, Leiden University Medical Center, Leiden, The Netherlands $u Department of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy
- 700 1_
- $a Bostrom, Peter J $u Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada $u Department of Urology, Turku University Hospital and University of Turku, Turku, Finland
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- 700 1_
- $a Neuzillet, Yann $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands $u Molecular Oncology Team, Institut Curie, CNRS, UMR144, PSL Research University, Paris, France $u Department of Urology, Hôpital Foch, UVSQ-Paris-Saclay University, Suresnes, France
- 700 1_
- $a Zlotta, Alexandre R $u Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Trombetta, Carlo $u Department of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy
- 700 1_
- $a Eckstein, Markus $u Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 700 1_
- $a Mertens, Laura S $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Bussani, Rossana $u Department of Pathology, University of Trieste, Trieste, Italy
- 700 1_
- $a Burger, Maximilian $u Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Boormans, Joost L $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a Wullich, Bernd $u Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 700 1_
- $a Hartmann, Arndt $u Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 700 1_
- $a Mayr, Roman $u Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Pavan, Nicola $u Department of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy
- 700 1_
- $a Bartoletti, Riccardo $u Department of Translational Research and New Technologies, Unit of Urology, University of Pisa, Pisa, Italy
- 700 1_
- $a Mir, M Carmen $u Department of Urology, Hospital Universitario La Ribera, Valencia, Spain
- 700 1_
- $a Pouessel, Damien $u Molecular Oncology Team, Institut Curie, CNRS, UMR144, PSL Research University, Paris, France $u Department of Medical Oncology, Claudius Regaud Institute, Toulouse University Cancer Center (IUCT) Oncopole, Toulouse, France
- 700 1_
- $a van der Hoeven, John $u Department of Urology, Reinier de Graaf Hospital, Delft, The Netherlands
- 700 1_
- $a van der Kwast, Theo H $u Department of Pathology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Allory, Yves $u Molecular Oncology Team, Institut Curie, CNRS, UMR144, PSL Research University, Paris, France $u Department of Pathology, Institut Curie, Paris, France
- 700 1_
- $a Zuiverloon, Tahlita C M $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a Lotan, Yair $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
- 700 1_
- $a van Rhijn, Bas W G $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands $u Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada $u Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany
- 773 0_
- $w MED00215624 $t Bladder cancer $x 2352-3735 $g Roč. 10, č. 2 (2024), s. 119-132
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39131875 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016081835 $b ABA008
- 999 __
- $a ok $b bmc $g 2196533 $s 1230301
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 10 $c 2 $d 119-132 $e 20240618 $i 2352-3735 $m Bladder cancer $n Bladder Cancer $x MED00215624
- LZP __
- $a Pubmed-20241008
